Annovis Bio (ANVS) had its "buy" rating reaffirmed by Canaccord Genuity Group Inc.. They now have a $17.00 price target on the stock.
Annovis Closes $10 Million Offering, Extending Cash Runway Through Phase 3 Alzheimer's Disease 6-Month NDA Submission
Annovis Announces $10 Million Underwritten Offering of Common Stock and Accompanying Warrants
Annovis Secures U.S. Patent for Buntanetap in the Prevention and Treatment of Neurological Injuries Caused by Brain Infections
InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Highlights Buntanetap Development in The Scientist Publication [TheStreet.com]